Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Authors: Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie‐Lorraine Chrétien, Thomas Dejoie, Sabrina Mahéo, Anne-Marie Stoppa, Brigitte Pegourié, Lionel Karlin, Laurent Garderet, Bertrand Arnulf, Chantal Doyen, Nathalie Meuleman, Bruno Royer, Jean‐Richard Eveillard, Lotfi Benboubker, Mamoun Dib, Olivier Decaux, Arnaud Jaccard, Karim Belhadj, Sabine Bréchignac, Brigitte Kolb, Cécile Fohrer, Mohamad Mohty, Margaret Macro, Paul G. Richardson, Victoria Carlton, Martin Moorhead, Tom Willis, Malek Faham, Kenneth C. Anderson, Jean‐Luc Harousseau, Xavier Leleu, Thierry Façon, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Nikhil C. Munshi - Blood 2018 cited by 420

= .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.